ScholarIQanswers from OpenAlex & ORCID
Florence Dalenc
ResearcherPublications, citations & collaboration network
Florence Dalenc is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Florence Dalenc have?
ScholarIQindexed works
Florence Dalenc has 564 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Florence Dalenc have?
ScholarIQcitation count
Florence Dalenc has 16,206 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Florence Dalenc?
ScholarIQh-index
Florence Dalenc has an h-index of 55 in OpenAlex.
What is the i10-index of Florence Dalenc?
ScholarIQi10-index
Florence Dalenc has an i10-index of 174 in OpenAlex.
What is the ORCID of Florence Dalenc?
ScholarIQorcid
The ORCID for Florence Dalenc is on the source record.
What is the OpenAlex record for Florence Dalenc?
ScholarIQopenalex
The OpenAlex for Florence Dalenc is on the source record.
What are the most-cited papers on Florence Dalenc?
ScholarIQmost cited works
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
François‐Clément Bidard, Virginia Kaklamani, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frédéric Forget, Marie‐Ange Mouret‐Reynier, Joohyuk Sohn, Donatienne Taylor, Kathleen Harnden, Hung T. Khong, Judit Kocsis, Florence Dalenc, Patrick M. Dillon, Sunil Babu, Simon Waters, Ines Deleu, José Á. García-Sáenz, Emilio Bria, Marina Elena Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortés, Shubin Liu, Giulia Tonini, Dirk Laurent, Nassir Habboubi, Maureen G. Conlan, Aditya Bardia
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Aditya Bardia, Sara M. Tolaney, Kevin Punie, Delphine Loirat, Mafalda Oliveira, Kevin Kalinsky, Amelia Zelnak, Philippe Aftimos, Florence Dalenc, Sagar Sardesai, Erika Hamilton, Priyanka Sharma, Sabela Recalde, Eva Ciruelos Gil, T Traina, Joyce O’Shaughnessy, Javier Cortés, Mu‐Hung Tsai, Linda T. Vahdat, Véronique Dièras, Lisa A. Carey, Hope S. Rugo, David M. Goldenberg, Q. Hong, Martin Olivo, Loretta M. Itri, Sara A. Hurvitz
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
Paul Cottu, Véronique D’Hondt, Sylvain Dureau, F. Lerebours, Isabelle Desmoulins, Pierre‐Etienne Heudel, FP Duhoux, Christelle Lévy, Marie‐Ange Mouret‐Reynier, Florence Dalenc, Jean‐Sébastien Frenel, Christelle Jouannaud, Laurence Venat‐Bouvet, Suzanne Nguyen, J-M. Ferrero, Jean Luc Canon, John‐Paul Grenier, Céline Callens, David Gentien, Jérôme Lemonnier, Anne Vincent‐Salomon, Suzette Delaloge